AU2022226409A1 — Formulations for aerosol formation and aerosols for the delivery of nucleic acid
Assigned to Ethris GmbH · Expires 2023-08-10 · 3y expired
What this patent protects
The invention relates to an aqueous suspension formulation for aerosol formation, said suspension formulation comprising lipid or lipidoid nanoparticles which are suspended in an aqueous vehicle solution, wherein the lipid or lipidoid nanoparticles comprise the following componen…
USPTO Abstract
The invention relates to an aqueous suspension formulation for aerosol formation, said suspension formulation comprising lipid or lipidoid nanoparticles which are suspended in an aqueous vehicle solution, wherein the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a nucleic acid and (b) an ionizable lipid or an ionizable lipidoid; and wherein the aqueous vehicle solution comprises a triblock copolymer which contains one polypropylene oxide) block and two poly(ethylene oxide) blocks. Moreover, the invention relates to an aerosol obtained from the formulation for aerosol formation.
Drugs covered by this patent
- Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.